BD Appoints Bilal Muhsin as EVP and President of Connected Care to Accelerate 'New BD' Strategy

Recently, according to Fierce Biotech, BD announced the appointment of Bilal Muhsin as Executive Vice President. He will also serve as the President of BD's "Connected Care" division, one of the company’s four major divisions. This appointment takes effect immediately from the date of the announcement.

It is reported that Bilal Muhsin is a veteran of Masimo, having been with the company for 25 years, during which he served as Executive Vice President of Engineering, Marketing, and Regulatory Affairs. Established in 1989, Masimo is a globally recognized leader in non-invasive monitoring technology, dedicated to developing and manufacturing various cutting-edge monitoring technologies and devices for the medical industry, including measurement devices, sensors, pulse oximeters, patient monitors, and automated equipment.

After joining BD Medical this time, Bilal Mushin will lead the strategic planning efforts, report to Tom Polen, Chairman, CEO, and President of BD, and participate in decision-making as a core member of BD's Global Executive Leadership Team.

Tom Polen has high hopes for the newly appointed leader, stating that Bilal possesses extensive and profound knowledge in connected care technology, software, and informatics strategy, coupled with his intense focus on customers, which will have a profound impact on BD. BD Medical will advance our connected care strategy through cutting-edge, AI-driven technologies, transforming patient care by enhancing safety, efficiency, and treatment outcomes.

He emphasized that the new personnel appointments are also part of implementing the "New BD" strategy, and this appointment marks another step towards becoming a differentiated leader in pure medical technology. Bilal will play a key role in helping BD leverage its significant advantages in digital, robotics, and artificial intelligence technological innovations to accelerate BD's healthcare growth and impact on healthcare.

Notably, on February 5 this year, BD announced the significant news of its business spin-off, formally deciding to divest its Biosciences and Diagnostic Solutions segments, which are valued at approximately $30 billion. After the adjustment, the new BD will become a pure medical device company with four business segments:

Medical essentials (infusion, blood collection and other consumables, with an annual shipment volume exceeding 10 billion pieces, stable cash flow);

Connected Care (Smart Pharmacy, Patient Monitoring, AI and Automation Driving Efficiency Improvement);

Biopharmaceutical Systems (Biologic Injection Devices, Benefiting from the Surge in Demand for Self-Injection Therapies such as GLP-1);

Interventional Therapy (Innovative Solutions for Chronic Diseases such as Urology, Peripheral Vascular, and Oncology).

In the future, BD Medical will rely on the basic market of essential medical consumables and extend to high value-added fields (such as GLP-1 drug supporting devices and AI pharmacies), aiming to become a "benchmark for medical technology innovation." Moreover, the "New BD" strategy also plans to carry out more complementary acquisitions along these directions. BD Medical launched its "BD 2025" plan for the first time in 2020, targeting an annual revenue growth of 5.5% or higher.

The spun-off life sciences business will independently operate life science tools and diagnostics, focusing on high-growth areas such as flow cytometry, microbial testing, and molecular diagnostics. Its future will benefit from the demand for precision medicine and infectious disease testing, with technical barriers (such as flow cytometers and molecular diagnostics) supporting high-margin growth.

Editor: Muyan

Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of PharmNet. We welcome discussions and additional insights in the comment section; for reprints, please be sure to credit the author and source. If there are any issues regarding the content, copyright, or other aspects of the work, please leave a message on this platform, and we will address it promptly.